← Back to Search

Treatment for Retinal Dystrophy

N/A
Recruiting
Research Sponsored by PYC Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through year 4
Awards & highlights

Summary

The purpose of this study is to characterize the natural history through temporal systemic evaluation of subjects identified with PRPF31 mutation-associated retinal dystrophy, also called retinitis pigmentosa type 11, or RP11. Assessments will be completed to measure and evaluate structural and functional visual changes including those impacting patient quality of life associated with this inherited retinal condition and observing how these changes evolve over time.

Eligible Conditions
  • Retinal Dystrophy
  • Retinitis Pigmentosa
  • Eye Diseases

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through year 4
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through year 4 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change from Baseline in Area of Fundus Autofluorescence (FAF)
Change from Baseline in Best Corrected Visual Acuity (BCVA)
Change from Baseline in Electrical response
+15 more

Find a Location

Who is running the clinical trial?

PYC TherapeuticsLead Sponsor
4 Previous Clinical Trials
90 Total Patients Enrolled
1 Trials studying Retinal Dystrophy
20 Patients Enrolled for Retinal Dystrophy
Sreenivasu Mudumba, PhDStudy ChairPYC Therapeutics
1 Previous Clinical Trials
40 Total Patients Enrolled
Glenn Noronha, PhDStudy ChairPYC Therapeutics
~25 spots leftby Dec 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top